Molecular-targeted therapy is a novel strategy born from our increasing understanding of the underlying pathways and key molecules involved in tumor growth and progression. Theoretically, the specificity of molecular targeted therapy should improve the therapeutic window by affecting the tumor cells and sparing normal cell.
The global Molecular Targeted Therapy market was valued at US$ 139 million in 2023 and is anticipated to reach US$ 261.5 million by 2030, witnessing a CAGR of 10.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Molecular Targeted Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Molecular Targeted Therapy.
Report Scope
The Molecular Targeted Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Molecular Targeted Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Molecular Targeted Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Phoenix Molecular Designs
Prelude Therapeutics
Tempus
Bracco
iOmx Therapeutics
OncoDNA
Sapience Therapeutics
Caris Life Sciences
Hera Biolabs
CV6 Therapeutics
Carrick Therapeutics
Foundation Medicine
Cybrexa Therapeutics
Segment by Type
Monoclonal Antibodies
Small Molecule Inhibitors
Segment by Application
Lung Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Molecular Targeted Therapy companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Molecular Targeted Therapy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibodies
1.2.3 Small Molecule Inhibitors
1.3 Market by Application
1.3.1 Global Molecular Targeted Therapy Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Leukemia
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Molecular Targeted Therapy Market Perspective (2019-2030)
2.2 Molecular Targeted Therapy Growth Trends by Region
2.2.1 Global Molecular Targeted Therapy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Molecular Targeted Therapy Historic Market Size by Region (2019-2024)
2.2.3 Molecular Targeted Therapy Forecasted Market Size by Region (2025-2030)
2.3 Molecular Targeted Therapy Market Dynamics
2.3.1 Molecular Targeted Therapy Industry Trends
2.3.2 Molecular Targeted Therapy Market Drivers
2.3.3 Molecular Targeted Therapy Market Challenges
2.3.4 Molecular Targeted Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Molecular Targeted Therapy Players by Revenue
3.1.1 Global Top Molecular Targeted Therapy Players by Revenue (2019-2024)
3.1.2 Global Molecular Targeted Therapy Revenue Market Share by Players (2019-2024)
3.2 Global Molecular Targeted Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Molecular Targeted Therapy Revenue
3.4 Global Molecular Targeted Therapy Market Concentration Ratio
3.4.1 Global Molecular Targeted Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Molecular Targeted Therapy Revenue in 2023
3.5 Molecular Targeted Therapy Key Players Head office and Area Served
3.6 Key Players Molecular Targeted Therapy Product Solution and Service
3.7 Date of Enter into Molecular Targeted Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Molecular Targeted Therapy Breakdown Data by Type
4.1 Global Molecular Targeted Therapy Historic Market Size by Type (2019-2024)
4.2 Global Molecular Targeted Therapy Forecasted Market Size by Type (2025-2030)
5 Molecular Targeted Therapy Breakdown Data by Application
5.1 Global Molecular Targeted Therapy Historic Market Size by Application (2019-2024)
5.2 Global Molecular Targeted Therapy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Molecular Targeted Therapy Market Size (2019-2030)
6.2 North America Molecular Targeted Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Molecular Targeted Therapy Market Size by Country (2019-2024)
6.4 North America Molecular Targeted Therapy Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Molecular Targeted Therapy Market Size (2019-2030)
7.2 Europe Molecular Targeted Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Molecular Targeted Therapy Market Size by Country (2019-2024)
7.4 Europe Molecular Targeted Therapy Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Molecular Targeted Therapy Market Size (2019-2030)
8.2 Asia-Pacific Molecular Targeted Therapy Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Molecular Targeted Therapy Market Size by Region (2019-2024)
8.4 Asia-Pacific Molecular Targeted Therapy Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Molecular Targeted Therapy Market Size (2019-2030)
9.2 Latin America Molecular Targeted Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Molecular Targeted Therapy Market Size by Country (2019-2024)
9.4 Latin America Molecular Targeted Therapy Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Molecular Targeted Therapy Market Size (2019-2030)
10.2 Middle East & Africa Molecular Targeted Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Molecular Targeted Therapy Market Size by Country (2019-2024)
10.4 Middle East & Africa Molecular Targeted Therapy Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Phoenix Molecular Designs
11.1.1 Phoenix Molecular Designs Company Detail
11.1.2 Phoenix Molecular Designs Business Overview
11.1.3 Phoenix Molecular Designs Molecular Targeted Therapy Introduction
11.1.4 Phoenix Molecular Designs Revenue in Molecular Targeted Therapy Business (2019-2024)
11.1.5 Phoenix Molecular Designs Recent Development
11.2 Prelude Therapeutics
11.2.1 Prelude Therapeutics Company Detail
11.2.2 Prelude Therapeutics Business Overview
11.2.3 Prelude Therapeutics Molecular Targeted Therapy Introduction
11.2.4 Prelude Therapeutics Revenue in Molecular Targeted Therapy Business (2019-2024)
11.2.5 Prelude Therapeutics Recent Development
11.3 Tempus
11.3.1 Tempus Company Detail
11.3.2 Tempus Business Overview
11.3.3 Tempus Molecular Targeted Therapy Introduction
11.3.4 Tempus Revenue in Molecular Targeted Therapy Business (2019-2024)
11.3.5 Tempus Recent Development
11.4 Bracco
11.4.1 Bracco Company Detail
11.4.2 Bracco Business Overview
11.4.3 Bracco Molecular Targeted Therapy Introduction
11.4.4 Bracco Revenue in Molecular Targeted Therapy Business (2019-2024)
11.4.5 Bracco Recent Development
11.5 iOmx Therapeutics
11.5.1 iOmx Therapeutics Company Detail
11.5.2 iOmx Therapeutics Business Overview
11.5.3 iOmx Therapeutics Molecular Targeted Therapy Introduction
11.5.4 iOmx Therapeutics Revenue in Molecular Targeted Therapy Business (2019-2024)
11.5.5 iOmx Therapeutics Recent Development
11.6 OncoDNA
11.6.1 OncoDNA Company Detail
11.6.2 OncoDNA Business Overview
11.6.3 OncoDNA Molecular Targeted Therapy Introduction
11.6.4 OncoDNA Revenue in Molecular Targeted Therapy Business (2019-2024)
11.6.5 OncoDNA Recent Development
11.7 Sapience Therapeutics
11.7.1 Sapience Therapeutics Company Detail
11.7.2 Sapience Therapeutics Business Overview
11.7.3 Sapience Therapeutics Molecular Targeted Therapy Introduction
11.7.4 Sapience Therapeutics Revenue in Molecular Targeted Therapy Business (2019-2024)
11.7.5 Sapience Therapeutics Recent Development
11.8 Caris Life Sciences
11.8.1 Caris Life Sciences Company Detail
11.8.2 Caris Life Sciences Business Overview
11.8.3 Caris Life Sciences Molecular Targeted Therapy Introduction
11.8.4 Caris Life Sciences Revenue in Molecular Targeted Therapy Business (2019-2024)
11.8.5 Caris Life Sciences Recent Development
11.9 Hera Biolabs
11.9.1 Hera Biolabs Company Detail
11.9.2 Hera Biolabs Business Overview
11.9.3 Hera Biolabs Molecular Targeted Therapy Introduction
11.9.4 Hera Biolabs Revenue in Molecular Targeted Therapy Business (2019-2024)
11.9.5 Hera Biolabs Recent Development
11.10 CV6 Therapeutics
11.10.1 CV6 Therapeutics Company Detail
11.10.2 CV6 Therapeutics Business Overview
11.10.3 CV6 Therapeutics Molecular Targeted Therapy Introduction
11.10.4 CV6 Therapeutics Revenue in Molecular Targeted Therapy Business (2019-2024)
11.10.5 CV6 Therapeutics Recent Development
11.11 Carrick Therapeutics
11.11.1 Carrick Therapeutics Company Detail
11.11.2 Carrick Therapeutics Business Overview
11.11.3 Carrick Therapeutics Molecular Targeted Therapy Introduction
11.11.4 Carrick Therapeutics Revenue in Molecular Targeted Therapy Business (2019-2024)
11.11.5 Carrick Therapeutics Recent Development
11.12 Foundation Medicine
11.12.1 Foundation Medicine Company Detail
11.12.2 Foundation Medicine Business Overview
11.12.3 Foundation Medicine Molecular Targeted Therapy Introduction
11.12.4 Foundation Medicine Revenue in Molecular Targeted Therapy Business (2019-2024)
11.12.5 Foundation Medicine Recent Development
11.13 Cybrexa Therapeutics
11.13.1 Cybrexa Therapeutics Company Detail
11.13.2 Cybrexa Therapeutics Business Overview
11.13.3 Cybrexa Therapeutics Molecular Targeted Therapy Introduction
11.13.4 Cybrexa Therapeutics Revenue in Molecular Targeted Therapy Business (2019-2024)
11.13.5 Cybrexa Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Phoenix Molecular Designs
Prelude Therapeutics
Tempus
Bracco
iOmx Therapeutics
OncoDNA
Sapience Therapeutics
Caris Life Sciences
Hera Biolabs
CV6 Therapeutics
Carrick Therapeutics
Foundation Medicine
Cybrexa Therapeutics
听
听
*If Applicable.
